Obstructive sleep apnoea and atrial fibrillation: are we on time?!

Francesco Maria Angelo Brasca,Elisa Perger
DOI: https://doi.org/10.1136/openhrt-2024-002859
2024-10-02
Open Heart
Abstract:Editorial on 'Cardiac remodelling in patients with AF and OSA' by T-E Hunt and coauthors The study by Hunt and coauthors focuses attention on possible positive cardiac remodelling following continuous positive airway pressure (CPAP) treatment. They analyse patients with paroxysmal atrial fibrillation (AF), mainly treated with pulmonary vein isolation (PVI), randomised to CPAP treatment or standard care, finding no significant differences in left ventricular (LV) ejection fraction, LV global longitudinal strain, left atrial volume index, left atrial reservoir strain and right atrium area. These results seem to raise a doubt on the efficacy of CPAP treatment for obstructive sleep apnoea (OSA). This point needs to be clarified. CPAP is the first-line treatment for OSA. Benefits on sleep disorders are well demonstrated, reducing the count of apnoea and hypopnoea per hour of sleep and the hypoxic and the hypercapnic burden. Nevertheless, despite encouraging results in observational studies, CPAP treatment has proven a neutral effect on secondary cardiovascular prevention in randomised controlled trials (RCTs).1–3 OSA has been involved in cardiovascular diseases with many pathophysiological mechanisms and, in particular, it acts both as a trigger and as a negative factor for structural modification in the setting of cardiac arrhythmias. Specifically, recurring apnoea–hypopnoea episodes, cortical arousals ...
What problem does this paper attempt to address?